S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
66,000% upside on tiny biotech? (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
Final stage before digital money (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
Final stage before digital money (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:HILS

Hillstream BioPharma (HILS) Stock Forecast, Price & News

$0.37
+0.02 (+5.64%)
(As of 05/26/2023 ET)
Compare
Today's Range
$0.35
▼
$0.37
50-Day Range
$0.35
▼
$1.09
52-Week Range
$0.30
▼
$2.65
Volume
199,464 shs
Average Volume
720,048 shs
Market Capitalization
$4.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Hillstream BioPharma MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
7.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.63mentions of Hillstream BioPharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.27) to ($0.10) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.25 out of 5 stars

See Top Rated MarketRank™ Stocks Here

HILS stock logo

About Hillstream BioPharma (NASDAQ:HILS) Stock

Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar IC50 against PI3K-delta and HDAC6, which is also known to downregulate; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2017 and is based in Bridgewater, New Jersey.

Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HILS Stock News Headlines

May 15, 2023 | finance.yahoo.com
Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson
May 4, 2023 | finanznachrichten.de
Hillstream BioPharma, Inc.: Hillstream BioPharma Announces Closing of Public Offering of Common Stock
May 28, 2023 | Behind the Markets (Ad)
[BREAKING] New "Living Missile" to Replace Nuclear Missiles
CBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!
May 2, 2023 | finance.yahoo.com
Hillstream BioPharma Announces Closing of Public Offering of Common Stock
May 2, 2023 | finance.yahoo.com
Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences
April 29, 2023 | benzinga.com
Hillstream BioPharma Stock (NASDAQ:HILS), Short Interest Report
April 28, 2023 | finanznachrichten.de
Hillstream BioPharma, Inc.: Hillstream BioPharma Announces Proposed Public Offering
April 28, 2023 | marketwatch.com
Hillstream BioPharma Shares Slide Premarket on Stock Offering >HILS
May 28, 2023 | Behind the Markets (Ad)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
April 28, 2023 | investorplace.com
Why Is Hillstream BioPharma (HILS) Stock Down 57% Today?
April 28, 2023 | finanznachrichten.de
Hillstream BioPharma, Inc.: Hillstream BioPharma Announces Pricing of Public Offering
April 27, 2023 | finance.yahoo.com
Hillstream BioPharma Announces Pricing of Public Offering
April 27, 2023 | finance.yahoo.com
Hillstream BioPharma Announces Proposed Public Offering
April 13, 2023 | tmcnet.com
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical
April 13, 2023 | finance.yahoo.com
Hillstream BioPharma Selects OncoBay Clinical to Advance Clinical and Regulatory Development for its Lead Drug Candidate HSB-1216, an Anti-Cancer Mechanism
April 12, 2023 | finance.yahoo.com
Hillstream BioPharma’s Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 11, 2023 | benzinga.com
Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow
April 10, 2023 | finance.yahoo.com
Hillstream BioPharma Announces Pharmacokinetic Data of HSB-1216 Supportive of its Development Strategy and Pre-clinical Data
March 28, 2023 | finance.yahoo.com
Hillstream BioPharma to Participate in Two Major Industry Conferences in April 2023
March 23, 2023 | americanbankingnews.com
Dawson James Weighs in on Hillstream BioPharma, Inc.'s Q2 2023 Earnings (NASDAQ:HILS)
February 28, 2023 | finance.yahoo.com
Hillstream BioPharma to Attend the 35th Annual ROTH Conference on March 12-14, 2023
February 15, 2023 | finance.yahoo.com
Hillstream BioPharma Regains Compliance with Nasdaq Listing Minimum Bid Price Rule
February 13, 2023 | finance.yahoo.com
Hillstream BioPharma Provides Webcast for its R&D Day on February 14th, 2023 at 10:00am ET
February 13, 2023 | finance.yahoo.com
Hillstream BioPharma Signs Exclusive Option Agreement with Applied Biomedical Science Institute (ABSI) to License Technology for HER2 and HER3 to be Developed for Potential Treatments Against Drug Resistant Cancers Including HER2-Positive Metastatic Breast Cancer, Gastric Cancer, Lung Cancer and Ovarian Cancer
February 10, 2023 | baystreet.ca
Hillstream Nearly Doubles on Test Results
February 10, 2023 | msn.com
Hillstream Soars on Promising HSB-1216 Data in Lung Cancer
February 10, 2023 | finance.yahoo.com
In a KRAS G12C-mutated NSCLC cell line, Calu-1, Hillstream BioPharma Demonstrated Significantly Greater Tumor Inhibition Combining Pembrolizumab, an anti-PD-1 antibody, and HSB-1216, a Ferroptosis Inducer
See More Headlines
Receive HILS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hillstream BioPharma and its competitors with MarketBeat's FREE daily newsletter.

HILS Company Calendar

Today
5/28/2023
Next Earnings (Estimated)
8/10/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:HILS
CUSIP
N/A
CIK
1861657
Web
www.hillstreambio.com
Phone
908-955-3140
Fax
N/A
Employees
1
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-8,470,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-132.03%
Return on Assets
-113.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.10
Quick Ratio
5.84

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.28 per share
Price / Book
1.34

Miscellaneous

Outstanding Shares
11,510,000
Free Float
6,897,000
Market Cap
$4.31 million
Optionable
Not Optionable
Beta
3.25

Key Executives

  • Mr. Randy D. Milby MBA (Age 69)
    Pres, Chairman & CEO
  • Mr. Thomas P. Hess CPA (Age 59)
    MBA, Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













HILS Stock - Frequently Asked Questions

Should I buy or sell Hillstream BioPharma stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Hillstream BioPharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" HILS shares.
View HILS analyst ratings or view top-rated stocks.

How have HILS shares performed in 2023?

Hillstream BioPharma's stock was trading at $0.3898 at the start of the year. Since then, HILS stock has decreased by 3.9% and is now trading at $0.3745.
View the best growth stocks for 2023 here.

Are investors shorting Hillstream BioPharma?

Hillstream BioPharma saw a increase in short interest in May. As of May 15th, there was short interest totaling 263,600 shares, an increase of 60.8% from the April 30th total of 163,900 shares. Based on an average trading volume of 682,400 shares, the short-interest ratio is currently 0.4 days. Currently, 7.4% of the shares of the stock are short sold.
View Hillstream BioPharma's Short Interest.

When is Hillstream BioPharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023.
View our HILS earnings forecast.

When did Hillstream BioPharma IPO?

(HILS) raised $21 million in an initial public offering (IPO) on Wednesday, January 12th 2022. The company issued 3,750,000 shares at $5.00-$6.00 per share.

What is Hillstream BioPharma's stock symbol?

Hillstream BioPharma trades on the NASDAQ under the ticker symbol "HILS."

Who are Hillstream BioPharma's major shareholders?

Hillstream BioPharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.33%).
View institutional ownership trends.

How do I buy shares of Hillstream BioPharma?

Shares of HILS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hillstream BioPharma's stock price today?

One share of HILS stock can currently be purchased for approximately $0.37.

How much money does Hillstream BioPharma make?

Hillstream BioPharma (NASDAQ:HILS) has a market capitalization of $4.31 million.

How can I contact Hillstream BioPharma?

The official website for the company is www.hillstreambio.com. The company can be reached via phone at 908-955-3140 or via email at investorrelations@hillstreambio.com.

This page (NASDAQ:HILS) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -